期刊文献+

多器官受侵犯的浆母细胞淋巴瘤1例报告并文献复习 被引量:1

Treatment of plasmablastic lymphoma with multiple organ involvement: A case report and literature review
下载PDF
导出
摘要 目的:报道多器官受侵犯的浆母细胞淋巴瘤(PBL)1例探讨PBL的诊治。方法:总结1例多器官受侵犯的PBL临床资料及诊疗过程,并复习国内外文献。结果:女性,50岁,因发热伴右乳腺旁包块起病,持续高热,PET/CT检测提示出现鼻咽部、全身多发淋巴结肿大、肝脾脏的多脏器广泛受侵,经乳腺包块病理检查确诊为PBL,HIV阴性,而EBER阳性。根据Ann Arbor分期该病人为IV期b型,经过3个疗程CHOP+E化疗达到缓解。结论:PBL依据病理学检查确诊,没有标准治疗方案,早诊断和早治疗和预后分子的检测与预后密切相关。 Objective: To assess the pathology diagnosis and prognosis of plasmablastic lymphoma( PBL). Methods: One case of PBL with abnormal function of multiple organs was reposed with review of literature. Results: A female patient was admitted with a mass in her right breast and a persistent fever. Imaging by computed tomography and positron emission tomography indicated that the lesion had spread to multiple organs. Pathological result confirmed that the patient had plasmablastic lymphoma with positive Epstein- Barr virus and negative HIV. This patient was IV phase( B type). After 3 rounds of CHOP + E chemotherapy,the patient achieved complete remission. Conclusion:Diagnosis of PBL still depends on both clinical and pathological findings. At present there is no standard therapy. The molecules detection,early diagnosis and early treatment was closely related to prognosis of PBL.
出处 《现代肿瘤医学》 CAS 2014年第12期2958-2960,共3页 Journal of Modern Oncology
关键词 浆母细胞淋巴瘤 诊断 化疗 plasmablastic lymphoma diagnosis chemotherapy
  • 相关文献

参考文献15

  • 1Delecluse H J,Anagnostopoulos I,Dallenbach F,et al.Plasmablastic lymphomas in the oral cavity:A new entity associated with the human immunodeficiency virus infection[J].Blood,1997,89 (4):1413-1420.
  • 2Stein H,Harris NL,Campo E.Plasmablastic lymphoma[M].WHO PRESS,Geneva,Switzerland,2008:256-257.
  • 3Castillo JJ,Reagan JL.Plasmablastic lymphoma:a systematic review[J].Sci World J,2011,11:687-696.
  • 4Castillo JJ,Winer ES,Stachurski D,et al.Clinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma[J].Leuk Lymphomas,2010,51 (11):2047-2053.
  • 5Tavora F,Gonzalez-Cuyar LF,Sun CC,et al.Extra-oral plamablastic lymphoma:Report of a case and review of literature[J].Hum Pathol,2006,37(9):1233-1236.
  • 6Mansoor M,Alani FSS,Aslam MB,et al.A case report of cecal plasmablastic lymphoma in a HIV-negative patient[J].Eur J Gastroenterol Hepatol,2012,24 (3):332-335.
  • 7Mihaljevic BS,Todorovic MR,Andjelic BM,et al.Unusual presentation of gastric plasmablastic lymphoma in HIV-negative patient[J].Med Oncol,2012,29:1186-1189.
  • 8Wang J,Hermandez OJ,Sun F.Plasmablastic lymphoma involving breast:A case diagnosed by fine-needle aspiration and core needle biopsy[J].Diagn Cytopathol,2009,36(4):257-261.
  • 9Qing X,Sun N,Chang E,et al.Plasmablastic lymphoma may occur as a high-grade transformation from plasmacytoma[J].Exp Mol Pathol,2011,90:85-90.
  • 10Qing X,Sun N,French SW,et al.Oral and extraoral plasmablastic lymphoma:similarities and differences in clinicopathologic characteristics[J].Am J Clin Pathol,2011,135:977-998.

二级参考文献14

  • 1Banks P M, Chan J, Cleary M L, et al. Mantle cell lymphoma:A proposal for unification of morphologic, immunologic and mo leculardata[J]. AmJ SurgPathol, 1992, 16(7) :637-640.
  • 2Wei A H, Roberts A W. Bortezomib: putting mantle cell lym phoma on death row[J]. Leuk Lymphoma,2008,49(4):657- 658.
  • 3Suh N S, Goy A. Bortezomib in mantle cell lymphoma[J]. Fu- ture Oncol, 2008, 4(2): 149-168.
  • 4Jares P, Colomer D, Canmpo E. Genetic and molecular patho- genesis of mantle cell lymphoma: Perspectives for new targeted therapeutics[J].Nat RevCancer, 2007,7(1) :750-754.
  • 5Ghielmini M, Zucca E. How I treat mantle cell lymphoma[J].Blood,2009, 114(8) :1469-1476.
  • 6Belaud-Rotureau M A, Parrens M, Dubus P, et al. A compara tive analysis of FISH, RT-PCR, PCR, and immunohistochemis try for the diagnosis of mantle cell lymphomas[J].Mod Pathol, 2002,15 (5) : 517-525.
  • 7Schmidt C, Dreyling M. Therapy of mantle cell lymphoma: cur rent standards and future strategies[J].Hematol Oncol Clin North Am, 2008, 22(5):953-963.
  • 8Kasamon Y L. Blood or marrow transplantation for mantle cell lymphoma[J]. Curr Opin Oncol, 2007, 19 (2) :128-135.
  • 9Wang M, Han X H, Zhang L, et al. Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo[J].Leukemia, 2008, 22(1) :179-185.
  • 10Goy A, Bernstein S H, Kahl B S, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time- to event analyses of the multicenter phase 2 PINNACLE study [J]. AnnOncol, 2009, 20(3):520-525.

共引文献4

同被引文献6

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部